Page 131 - Haematologica July

Chronic Lymphocytic Leukemia
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
Antonio Cuneo,1 George Follows,2 Gian Matteo Rigolin,1 Alfonso Piciocchi,3 Alessandra Tedeschi,4 Livio Trentin,5 Angeles Medina Perez,6 Marta Coscia,7 Luca Laurenti,8 Gerardo Musuraca,9 Lucia Farina,10 Alfredo Rivas Delgado,11 Ester Maria Orlandi,12 Piero Galieni,13 Francesca Romana Mauro,14 Carlo Visco,15 Angela Amendola,16 Atto Billio,17 Roberto Marasca,18 Annalisa Chiarenza,19 Vittorio Meneghini,20 Fiorella Ilariucci,21 Monia Marchetti,22 Stefano Molica,23 Francesca Re,24 Gianluca Gaidano,25 Marcos Gonzalez,26 Francesco Forconi,27 Stefania Ciolli,28 Agostino Cortelezzi,29 Marco Montillo,4 Lukas Smolej,30 Anna Schuh,31
Toby A. Eyre,32 Ben Kennedy,33 Kris M. Bowles,34 Marco Vignetti,3 Javier de la Serna,35 Carol Moreno,36 Robin Foà14 and Paolo Ghia37 on behalf of the GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum
1Hematology, Department of Medical Sciences, St. Anna University Hospital, Ferrara, Italy; 2UK CLL Forum, Cambridge University Hospitals NHS Foundation Trust, UK; 3Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy; 4Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; 5Hematology and Clinical Immunology, Department of Medicine, University of Padua, Italy; 6Hospital Costa del Sol, Marbella, Málaga, Spain; 7Hematology Unit, Città della Salute e della Scienza, University of Turin, Italy; 8Hematology, Università Cattolica del Sacro Cuore, Policlinico A. Gemelli, Rome, Italy; 9Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; 10Hematology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; 11Department of Hematology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; 12Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 13Hematology and Cellular Therapy, “Ospedale C. e G. Mazzoni”, Ascoli Piceno, Italy; 14Hematology, Department of Biomedical Sciences and Hematology, "Sapienza" University, Rome, Italy; 15Hematology, San Bortolo Hospital, Vicenza, Italy; 16Hematology, San Carlo Hospital, Potenza, Italy; 17Hematology and Transplant Unit, San Maurizio Hospital, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; 18Hematology Unit, University Hospital, Modena, Italy; 19Hematology Unit, Azienda Universitaria Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy; 20Hematology, Department of Cell Therapy and Hematology, University Hospital, Verona, Italy; 21Hematology Unit, Arcispedale S. Maria Nuova, Reggio Emilia, Italy; 22Oncology Unit, Cardinal Massaia Hospital, Asti, Italy; 23Hematology Unit, A. Pugliese Hospital, Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy; 24Hematology, University Hospital, Parma, Italy; 25Hematology, DIMECS e Dipartimento Oncologico, Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy; 26Hematology, University Hospital-IBSAL and CIBERONC, Salamanca, Spain; 27Haematology Department, University Hospital National Health Service Trust, Southampton, UK; 28Hematology Unit, Careggi Hospital, Florence, Italy; 29Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Italy; 30Department of Hematology, University Hospital, Hradec Kralove, Czech Republic; 31UK CLL Forum, Oxford University Hospitals NHS Foundation Trust, UK; 32Oxford University Hospitals NHS Foundation Trust, UK; 33University Hospitals of Leicester NHS Trust, UK; 34Norwich Medical School, UK; 35Hematology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; 36Hospital de la Santa Creu i Sant Pau, Barcellona, Spain and 37Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy
Ferrata Storti Foundation
AC and GF contributed equally to this work as first authors. RF and PG contributed equally to this work as last authors
Haematologica 2018 Volume 103(7):1209-1217
ABSTRACT
We performed an observational study on the efficacy of ben- damustine and rituximab (BR) as first salvage regimen in chron- ic lymphocytic leukemia (CLL). In an intention-to-treat analy- sis including 237 patients, the median progression-free survival (PFS) was 25 months. The presence of del(17p), unmutated IGHV and advanced stage were associated with a shorter PFS at multivariate analysis. The
Correspondence:
cut@unife.it
Received: February 6, 2018. Accepted: April 18, 2018. Pre-published: April 19, 2018.
doi:10.3324/haematol.2018.189837
Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/103/7/1209
©2018 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or inter- nal use. Sharing published material for non-commercial pur- poses is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for com- mercial purposes is not allowed without permission in writing from the publisher.
haematologica | 2018; 103(7)
1209
ARTICLE